Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Razuprotafib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB known ✓ | P23467 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Razuprotafib SCHEMBL17083766 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL679459 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083328 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083324 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083320 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083334 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL468232 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083759 | 1.00 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL467857 | 0.99 | PTPRB (0.98) | PTPRB | |
| Razuprotafib SCHEMBL467855 | 0.99 | PTPRB (0.98) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | claimed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | claimed |
| US-20230398100-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230398100-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11666558-B2 | Methods of treating intraocular pressure with activators of Tie-2 | EyePoint Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666558-B2 | Methods of treating intraocular pressure with activators of Tie-2 | EyePoint Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230139250-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | EYEPOINT PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139250-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | EYEPOINT PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022133232-A1 | METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133078-A1 | DOSAGE FORMS OF TIE-2 ACTIVATORS | EyePoint Pharmaceuticals, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20170079959-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20170079959-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9539245-B2 | Combination of immunotherapies with activators of Tie-2 | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539245-B2 | Combination of immunotherapies with activators of Tie-2 | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160038467-A1 | Combination of Immunotherapies with Activators of Tie-2 | EyePoint, Inc. | 2016-02-11 | — | — | US | disclosed |
| US-20160038467-A1 | Combination of Immunotherapies with Activators of Tie-2 | EyePoint, Inc. | 2016-02-11 | — | — | US | disclosed |
| US-20150259335-A1 | HPTP-BETA INHIBITORS | AERPIO THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259335-A1 | HPTP-BETA INHIBITORS | AERPIO THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| WO-2015138882-A1 | HPTP-BETA INHIBITORS | AERPIO THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259335-A1 | HPTP-BETA INHIBITORS | TEK, TIE1, PITPNB | PTPRB 718/4885 |
| US-20170079959-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | TIE1, TEK, VASP | PTPRB 1545/4885 |
| US-20230398100-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | TIE1, TEK, VASP | PTPRB 1545/4885 |
| US-20160038467-A1 | Combination of Immunotherapies with Activators of Tie-2 | TIE1, TEK, PDCD1LG2 | PTPRB 299/4885 |
| US-11666558-B2 | Methods of treating intraocular pressure with activators of Tie-2 | TIE1, TEK, VASP | PTPRB 1545/4885 |
| US-20230139250-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | TIE1, TEK, KDR | PTPRB 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.